Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI)

Sumanta Pal; Javier Puente; Daniel Heng; Hilary Glen; Koralewski Piotr; Daniil Stroyakovskiy; Boris Alekseev; Francis Parnis; Daniel Castellano; Kaisa Sunela; Tudor Ciuleanu; Jae-Lyun Lee; Karen O´Hara

doi:10.1200/JCO.2021.39.6_suppl.307

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI)

Sumanta Pal
, Javier Puente
, Daniel Heng
, Hilary Glen
, Koralewski Piotr
, Daniil Stroyakovskiy
, Boris Alekseev
, Francis Parnis
, Daniel Castellano
, Kaisa Sunela
, Tudor Ciuleanu
, Jae-Lyun Lee
, Karen O´Hara

Tutkimustuotos: Muu konferenssimateriaali › Abstrakti › Tieteellinen

Alkuperäiskieli	Englanti
DOI - pysyväislinkit	https://doi.org/10.1200/JCO.2021.39.6_suppl.307
Tila	Julkaistu - 2021
OKM-julkaisutyyppi	Ei OKM-tyyppiä
Tapahtuma	Genitourinary Cancers Symposium - Kesto: 11 helmik. 2021 → 13 helmik. 2021 https://meetings.asco.org/gu/connect

Conference

Conference	Genitourinary Cancers Symposium
Ajanjakso	11/02/21 → 13/02/21
www-osoite	https://meetings.asco.org/gu/connect

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

SDG 3 – Hyvä terveys ja hyvinvointi

Pääsy asiakirjaan

10.1200/JCO.2021.39.6_suppl.307Lisenssi: Unspecified

Siteeraa tätä

Pal, S., Puente, J., Heng, D., Glen, H., Piotr, K., Stroyakovskiy, D., Alekseev, B., Parnis, F., Castellano, D., Sunela, K., Ciuleanu, T., Lee, J.-L., & O´Hara, K. (2021). Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Abstraktin lähde: Genitourinary Cancers Symposium . https://doi.org/10.1200/JCO.2021.39.6_suppl.307

@conference{eb9f0dcc3440491ea032e51fdbd7f8cf,

title = "Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI)",

author = "Sumanta Pal and Javier Puente and Daniel Heng and Hilary Glen and Koralewski Piotr and Daniil Stroyakovskiy and Boris Alekseev and Francis Parnis and Daniel Castellano and Kaisa Sunela and Tudor Ciuleanu and Jae-Lyun Lee and Karen O´Hara",

year = "2021",

doi = "10.1200/JCO.2021.39.6\_suppl.307",

language = "English",

note = "Genitourinary Cancers Symposium ; Conference date: 11-02-2021 Through 13-02-2021",

url = "https://meetings.asco.org/gu/connect",

}

Pal, S, Puente, J, Heng, D, Glen, H, Piotr, K, Stroyakovskiy, D, Alekseev, B, Parnis, F, Castellano, D, Sunela, K, Ciuleanu, T, Lee, J-L & O´Hara, K 2021, 'Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI)', Genitourinary Cancers Symposium , 11/02/21 - 13/02/21. https://doi.org/10.1200/JCO.2021.39.6_suppl.307

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). / Pal, Sumanta; Puente, Javier; Heng, Daniel et al.
2021. Abstraktin lähde: Genitourinary Cancers Symposium .

Tutkimustuotos: Muu konferenssimateriaali › Abstrakti › Tieteellinen

TY - CONF

T1 - Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC)

T2 - Genitourinary Cancers Symposium

AU - Pal, Sumanta

AU - Puente, Javier

AU - Heng, Daniel

AU - Glen, Hilary

AU - Piotr, Koralewski

AU - Stroyakovskiy, Daniil

AU - Alekseev, Boris

AU - Parnis, Francis

AU - Castellano, Daniel

AU - Sunela, Kaisa

AU - Ciuleanu, Tudor

AU - Lee, Jae-Lyun

AU - O´Hara, Karen

PY - 2021

Y1 - 2021

U2 - 10.1200/JCO.2021.39.6_suppl.307

DO - 10.1200/JCO.2021.39.6_suppl.307

M3 - Abstract

Y2 - 11 February 2021 through 13 February 2021

ER -

Pal S, Puente J, Heng D, Glen H, Piotr K, Stroyakovskiy D et al.. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). 2021. Abstraktin lähde: Genitourinary Cancers Symposium . doi: 10.1200/JCO.2021.39.6_suppl.307